Literature DB >> 9444956

Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential.

W Mao1, R Irby, D Coppola, L Fu, M Wloch, J Turner, H Yu, R Garcia, R Jove, T J Yeatman.   

Abstract

Recent data suggest that signal transduction may have a critical role in the development and regulation of the metastatic phenotype. Here, we investigated the role of c-Src activation in the process of human colon cancer metastasis to the liver. Our data, derived from two different sets of human colon cancer cell line metastatic variants, suggest that not only do highly-metastatic cells display constitutively elevated c-Src protein kinase activity when compared to poorly metastatic cells, but also that receptor tyrosine kinases participate in the ligand-activation of c-Src above basal levels. Specifically, the epidermal growth factor receptor (EGFR), p185HER2/Neu and the hepatocyte growth factor receptor (c-Met) appear to be linked to the process because they preferentially activate c-Src in highly-metastatic cells. EGFR was found to associate with c-Src in colon cancer cells and specific inhibitors of the EGFR resulted in a reduction of c-Src activity to basal levels. In addition, c-Src transfectants displayed partially-activated EGFRs, suggesting a feedback role for c-Src in the regulation of the EGFR. p185HER2/Neu was also identified in immunocomplexes of c-Src following ligand activation of the EGFR, but only in highly-metastatic cells. Collectively, these observations suggest a paradigm whereby c-Src interacts with multiple cell-surface growth factors in a catalytic fashion for the development of tumor cells with metastatic potential.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9444956     DOI: 10.1038/sj.onc.1201496

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  54 in total

1.  Hsp90 inhibition transiently activates Src kinase and promotes Src-dependent Akt and Erk activation.

Authors:  Fumitaka Koga; Wanping Xu; Tatiana S Karpova; James G McNally; Roland Baron; Len Neckers
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-14       Impact factor: 11.205

2.  The cell surface glycoprotein CUB domain-containing protein 1 (CDCP1) contributes to epidermal growth factor receptor-mediated cell migration.

Authors:  Ying Dong; Yaowu He; Leonore de Boer; M Sharon Stack; John W Lumley; Judith A Clements; John D Hooper
Journal:  J Biol Chem       Date:  2012-02-07       Impact factor: 5.157

3.  Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma.

Authors:  Priya Koppikar; Seung-Ho Choi; Ann Marie Egloff; Quan Cai; Shinsuke Suzuki; Maria Freilino; Hiroshi Nozawa; Sufi M Thomas; William E Gooding; Jill M Siegfried; Jennifer R Grandis
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

4.  Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.

Authors:  John H Strickler; Shannon McCall; Andrew B Nixon; John C Brady; Herbert Pang; Christel Rushing; Allen Cohn; Alexander Starodub; Christy Arrowood; Sherri Haley; Kellen L Meadows; Michael A Morse; Hope E Uronis; Gerard C Blobe; S David Hsu; S Yousuf Zafar; Herbert I Hurwitz
Journal:  Invest New Drugs       Date:  2013-11-01       Impact factor: 3.850

5.  A Phosphotyrosine Proteomic Screen Identifies Multiple Tyrosine Kinase Signaling Pathways Aberrantly Activated in Malignant Mesothelioma.

Authors:  Craig W Menges; Yibai Chen; Brooke T Mossman; Jonathan Chernoff; Anthony T Yeung; Joseph R Testa
Journal:  Genes Cancer       Date:  2010-05-01

6.  Paxillin regulates androgen- and epidermal growth factor-induced MAPK signaling and cell proliferation in prostate cancer cells.

Authors:  Aritro Sen; Katherine O'Malley; Zhou Wang; Ganesh V Raj; Donald B Defranco; Stephen R Hammes
Journal:  J Biol Chem       Date:  2010-07-13       Impact factor: 5.157

7.  Ligand activation of alternatively spliced fibroblast growth factor receptor-1 modulates pancreatic adenocarcinoma cell malignancy.

Authors:  Selwyn M Vickers; Zhi-Qiang Huang; LeeAnn MacMillan-Crow; Jessica S Greendorfer; John A Thompson
Journal:  J Gastrointest Surg       Date:  2002 Jul-Aug       Impact factor: 3.452

8.  Identification of pY654-β-catenin as a critical co-factor in hypoxia-inducible factor-1α signaling and tumor responses to hypoxia.

Authors:  Y Xi; Y Wei; B Sennino; A Ulsamer; I Kwan; A N Brumwell; K Tan; M K Aghi; D M McDonald; D M Jablons; H A Chapman
Journal:  Oncogene       Date:  2012-12-17       Impact factor: 9.867

9.  Dynamic deterministic effects propagation networks: learning signalling pathways from longitudinal protein array data.

Authors:  Christian Bender; Frauke Henjes; Holger Fröhlich; Stefan Wiemann; Ulrike Korf; Tim Beissbarth
Journal:  Bioinformatics       Date:  2010-09-15       Impact factor: 6.937

10.  Activity of the multikinase inhibitor dasatinib against ovarian cancer cells.

Authors:  G E Konecny; R Glas; J Dering; K Manivong; J Qi; R S Finn; G R Yang; K-L Hong; C Ginther; B Winterhoff; G Gao; J Brugge; D J Slamon
Journal:  Br J Cancer       Date:  2009-10-27       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.